Kurzfassung

To evaluate more immediate cardioversion , prospective trials comparing rivaroxaban (X-VeRT)  and edoxaban (ENSURE-AF) against heparin/VKA in patients undergoing cardioversion found comparable efficacy and safety with low event rates.